阿立哌唑与利培酮治疗精神分裂症的对照研究  

Comparative Study on the Effect of Aripiprazole and Risperidone on Schizophrenia

作　　者：麦桂英[1] 蔡广惠[1] 黄金满[1] 李英[1] 何广贤[1] 戴俊平[1] 

机构地区：[1]广州市精神病医院二科,广东广州510370

出　　处：《中国康复》2005年第3期184-185,共2页Chinese Journal of Rehabilitation

摘　　要：目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效。方法:72例符合CCMD3精神分裂症患者分为2组各36例,分别予阿立哌唑(A组)和利培酮(B组)治疗6周,采用阳性症状与阴性症状量表及不良反应症状量表评定疗效与副反应。结果:2组疗效及不良反应发生率比较差异无显著性意义。结论:阿立哌唑和利培酮对精神分裂症疗效相当,副反应差异亦不显著;但在锥体外系反应、内分泌改变及体重增加方面,阿立哌唑优于利培酮。Objective: To compare the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia. Methods: Seventy-two patients with sihizophrenia by CCMD-3 were randomly allocated to two groups treated with aripiprazole or resperidone respectively for 6 weeks. The Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Side effect Scale (TESS) were used to evaluate the efficacy and adverse effect respectively. Results: The clinical efficacy and the incidence of adverse effect in the two groups had no significant difference. Conclusion: Aripiprazole is as effective and safe as risperidone for the treatment of sihizophrenia and fewer side effect. The incidence of adverse effect in two drugs has no any significant difference. But It shows that aripiprazole is superior to risperidone in extrapyramidal symptoms, endocrine change and weight gain.

关 键 词：阿立哌唑 利培酮 精神分裂症 疗效 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]